Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma and its partner Vetbiolix have announced promising results from a clinical study in dogs with osteoarthritis, using the drug Piclidenoson. The successful trial outcomes may lead to Vetbiolix obtaining a full license agreement with Can-Fite, including upfront and milestone payments plus sales royalties upon regulatory approval. Can-Fite hopes to quickly bring Piclidenoson to the market, addressing a significant unmet need in the growing $3 billion canine osteoarthritis market.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
